Sana Biotechnology, Inc. SANA
We take great care to ensure that the data presented and summarized in this overview for Sana Biotechnology, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SANA
View all-
Flagship Pioneering Inc. Cambridge, MA25MShares$142 Million16.48% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.2MShares$69 Million0.0% of portfolio
-
Baillie Gifford & CO10.7MShares$60.5 Million0.08% of portfolio
-
Canada Pension Plan Investment Board Toronto Ontario, A610.2MShares$57.8 Million0.11% of portfolio
-
Black Rock Inc. New York, NY9.05MShares$51.4 Million0.0% of portfolio
-
State Street Corp Boston, MA6.37MShares$36.2 Million0.0% of portfolio
-
Capital World Investors Los Angeles, CA5.45MShares$31 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD4.8MShares$27.3 Million0.03% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.7MShares$21 Million0.0% of portfolio
-
Crestline Management, LP Fort Worth, TX3.37MShares$19.1 Million3.05% of portfolio
Latest Institutional Activity in SANA
Top Purchases
Top Sells
About SANA
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.
Insider Transactions at SANA
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Apr 05
2024
|
Hans Edgar Bishop |
BUY
Grant, award, or other acquisition
|
Direct |
2,774
+0.05%
|
-
|
Mar 08
2024
|
Patrick Y Yang |
SELL
Open market or private sale
|
Direct |
25,000
-14.35%
|
$225,000
$9.45 P/Share
|
Feb 08
2024
|
Robert Nelsen |
BUY
Open market or private purchase
|
Indirect |
1,818,181
+4.78%
|
$9,090,905
$5.5 P/Share
|
Feb 08
2024
|
Arch Venture Fund X, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,818,181
+4.78%
|
$9,090,905
$5.5 P/Share
|
Feb 08
2024
|
Keith Crandell > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,818,181
+4.78%
|
$9,090,905
$5.5 P/Share
|
Jan 05
2024
|
Mary Agnes Wilderotter |
BUY
Grant, award, or other acquisition
|
Direct |
1,470
+17.14%
|
-
|
Jan 05
2024
|
Hans Edgar Bishop |
BUY
Grant, award, or other acquisition
|
Direct |
4,901
+0.08%
|
-
|
Dec 15
2023
|
Christian Hordo EVP, Chief Business Officer |
SELL
Open market or private sale
|
Direct |
75,000
-7.96%
|
$300,000
$4.0 P/Share
|
Oct 05
2023
|
Hans Edgar Bishop |
BUY
Grant, award, or other acquisition
|
Direct |
6,925
+0.12%
|
-
|
Oct 05
2023
|
Mary Agnes Wilderotter |
BUY
Grant, award, or other acquisition
|
Direct |
2,077
+26.93%
|
-
|
Sep 13
2023
|
Flagship Pioneering Inc. |
SELL
Other acquisition or disposition
|
Indirect |
11,781,275
-52.11%
|
-
|
Jul 05
2023
|
Hans Edgar Bishop |
BUY
Grant, award, or other acquisition
|
Direct |
4,152
+0.07%
|
-
|
Jul 05
2023
|
Mary Agnes Wilderotter |
BUY
Grant, award, or other acquisition
|
Direct |
1,245
+25.92%
|
-
|
Jun 07
2023
|
Flagship Ventures Fund V General Partner LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
200,000
-1.62%
|
$1,200,000
$6.24 P/Share
|
Jun 06
2023
|
Flagship Ventures Fund V General Partner LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
203,758
-1.6%
|
$1,222,548
$6.31 P/Share
|
May 26
2023
|
Flagship Ventures Fund V General Partner LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
82,000
-0.65%
|
$492,000
$6.23 P/Share
|
May 25
2023
|
Flagship Ventures Fund V General Partner LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
115,372
-0.91%
|
$692,232
$6.35 P/Share
|
May 24
2023
|
Flagship Ventures Fund V General Partner LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
347,870
-2.66%
|
$2,087,220
$6.57 P/Share
|
Apr 05
2023
|
Hans Edgar Bishop |
BUY
Grant, award, or other acquisition
|
Direct |
7,716
+0.13%
|
-
|
Apr 05
2023
|
Mary Agnes Wilderotter |
BUY
Grant, award, or other acquisition
|
Direct |
2,314
+50.0%
|
-
|
Last 12 Months Summary
Open market or private purchase | 5.45M shares |
---|---|
Grant, award, or other acquisition | 23.5K shares |
Other acquisition or disposition | 11.8M shares |
---|---|
Open market or private sale | 100K shares |